RT Journal
A1 Kuehn BM
T1 NAtalizumab risks
JF JAMA
JO JAMA
YR 2010
FD March 24
VO 303
IS 12
SP 1139
OP 1139
DO 10.1001/jama.2010.301
UL http://dx.doi.org/10.1001/jama.2010.301
AB 
Natalizumab is approved by the FDA for the treatment of multiple sclerosis and Crohn disease. PML is a rare and deadly neurological infection caused by the JC virus, a nearly ubiquitous and usually benign virus that typically affects immunosuppressed individuals. The disorder is also associated with use of natalizumab, and the FDA has received 31 reports of such cases. Because of the risks, natalizumab is currently only available for use through a carefully monitored prescribing program.